Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Who keeps selling below the bid? I want his/her head on a plate! Lol
Where will we expect find the pr?
2 mins left - buy now or watch it double tomorrow without you. Lol
What’s going on? Tons of volume. I assume the suspension is lifted...
About $32,000,000 usd
I bought back in, hoping for another massive run.
You want proof - well here’s all the proof I need:
https://www.sec.gov/Archives/edgar/data/1557340/000107997320000919/optec_8k.htm
Big moves 2 days in a row.
This can easily move up to $10 a share by spring. COVID wrecked their plans for this year, but we’ve all adapted. VALE only shut down their mine for a few weeks up there, and on the western side the mines stayed open right through. So keep buying, as this is still the low end of the spectrum.
IMO
#LBRMF
I guess you never heard of OPTI.
That was the stick of the century, and it happened a few months ago.
I wish and hope and pray PVDG does 1/100 of what OPTI did. :)
Lol it will today.
The best stock I’ve ever owned, by far the most profit, and I sold at $0.046. Lol
It will be talked about on the OTC for years to come, and I don’t think it’s done yet.
Good luck to everyone still in it. Lots of millionaires made off of this one in the last 6-8 weeks.
$OPTI
And I’m out. Thanks OPTI - it was a lot of fun and a lot of money made.
I hope it continues to soar for everyone else here.
#OPTI
I’m not even tempted to start selling yet.
There’s still lots of steam left in this one yet. It’s unbelievable at this point, but I’ve said that several times already, and then it doubles again.
Go #OPTI!
We hear! ;)
Has anyone found the news yet?
Agreed. I have approximately 30 million shares. Averaged down to where if it goes to $0.0002 I make some money.
And unless Anish kicks the bucket, he will increase the stock price again as he has proven over and over (whether real or a scam).
If you can get cheap shares and you don’t mind letting them sit for a couple of years, then someday you will make good money off of them.
Example: I bought 40 million shares at $0.0001 approximately 5 years ago. Sold them for $0.0016 about 20 months or so ago. Walked away from it.
Bought some more for about 0.0005 about 16 months ago, and averaged down again to where I am today.
He may go to jail, he may RS, and then pump and dump, etc, but as long as he is alive he will provide coattails to ride on with his stocks.
Or not, but that’s the game down here.
Use your profits from the runs of others to buy cheap shares in these types of companies, who historically put them on runs.
All just IMHO.
Good luck!
This is the first DD on an OTC company that I was invested in, or about to invest in, (out of about 200 DD’s) where I came out of it saying “well at least they are a legitimate company.
So IMHO, I think we are fine with holding this one. They have a real and credentialed board, they have salaried lobbyist with great credentials, they have audited financials, and they are multiple exchanges.
Even if they are “pumping and dumping” (though the volume doesn’t indicate that over the last month in any way, nor does the charts), even if they do, it will be to pay for the next move to get this out there.
They have the look/feel/smell of a company that will be on the major exchanges in the foreseeable future.
Again, just my opinion from my dig.
Good luck!!
#AGNPF
A green close? Finally.
Is there anything happening?
Shorts lose money too. Trust me
My guess is somewhere around $0.80 this week, and on the next news up towards $2.50-$3.00.
That’s only if they don’t dilute a lot to raise cash for what they’ve promised to do once approved. Then we should just wait for a buyout.
I’m looking forward to this week for sure!
Algernon Provides an Overview of its NP-120 (Ifenprodil) Program for COVID-19
VANCOUVER, British Columbia, March 24, 2020 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to provide an overview of its multiple recent activities surrounding the investigation of its repurposed drug compound NP-120 (Ifenprodil), as a possible treatment for idiopathic pulmonary fibrosis (IPF), acute lung injury (ALI), chronic cough, and coronavirus (COVID-19).??
Background
Algernon is a drug re-purposing company that investigates safe, already approved drugs for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.???
One of the drugs Algernon has been investigating is a generic Sanofi neurological drug developed in the 1970’s called Ifenprodil, which is currently approved for use in South Korea and Japan.?
Algernon investigated Ifenprodil for IPF, which outperformed the world’s leading two IPF treatments Nintedanib and Pirfenidone, in a pre-clinical in vivo animal study, reducing fibrosis by 56% with statistical significance.???
Ifenprodil also outperformed Merck's phase 3 drug Gefapixant in a recent acute cough animal study by 110%.???
The Company intends to submit for ethics approval for a phase 2 clinical trial for Ifenprodil for IPF and chronic cough in Australia shortly.???
An independent study found that Ifenprodil significantly reduced ALI and improved survivability in an animal study with Avian H5N1 infected mice by 40% (as a result Algernon has decided to expand its Ifenprodil clinical program to include ALI and COVID-19 – read more below). Avian H5N1 is the most lethal form of influenza known to man with an over 50% mortality rate.???
Ifenprodil was also shown in a separate independently published in vivo study to prolong survival under anoxic (low oxygen) conditions, as might occur in patients with severely impaired lung function.
Update on Algernon’s Response to the COVID-19 Pandemic
The Company continues to develop Ifenprodil for IPF and chronic cough. However, as a result of the data from an independent study showing the drug’s performance in an animal study for H5N1, the Company has decided to expand its Ifenprodil clinical trial program to include ALI, a specific form of injury with diverse causes including influenza related pneumonia, and COVID-19.
Recent Algernon COVID-19 Initiatives:
March 13, 2020 – Algernon Filed a pre-IND (Investigational New Drug) meeting request with the U.S. FDA for the treatment and prevention of ALI and acute respiratory distress syndrome (ARDS) associated with COVID-19 infection. ?
March 13, 2020 - Algernon Contacts Gates Foundation Regarding Funding for the development of New COVID-19 Treatments.?
March 19, 2020 - Algernon announces support of a physician initiated planned Phase 2 trial of Ifenprodil for COVID-19 in South Korea.?
March 20, 2020 - Algernon appoints award winning Novotech as the contract research organization (“CRO”) for a planned physician initiated study of Ifenprodil for COVID-19 patients in South Korea.?
March 20, 2020 - Algernon retains Novotech to conduct a feasibility study in Australia for a phase 2 sponsor initiated Ifenprodil COVID-19 trial. Novotech has already identified 3 physicians who have indicated their interest to participate.?
March 23, 2020 - Algernon appoints U.S. Based Cascade Chemistry to support its quickly evolving clinical program for ALI, its urgent clinical focus on COVID-19 as well as its idiopathic pulmonary fibrosis (IPF) and chronic cough clinical program.
Summary
The Company remains confident that Ifenprodil, an approved drug in Japan and South Korea with a known, strong safety history, has demonstrated evidence it may be protective of the lung by reducing the damage that can be caused by ALI.
As a result, Algernon believes its potential as a re-purposed drug for utilization in immediate phase 2 clinical trials by researchers for the treatment of COVID-19 is clear and significant.
About NP-120 (Ifenprodil)
NP-120 (Ifenprodil) is an N-methyl-D-aspartate (NDMA) receptor glutamate receptor antagonist specifically targeting the NMDA-type subunit 2B (Glu2NB). Ifenprodil also exhibits agonist activity for the Sigma-1 receptor, a chaperone protein up-regulated during endoplasmic reticulum stress. Although the anti-fibrotic activity of Ifenprodil in IPF is not known, recent studies have suggested a link between both receptors and pathways associated with fibrosis.
Glutamate (Glu) is the main excitatory neurotransmitter which acts on glutamate receptors in the central nervous system (CNS) but overactivation of these receptors can cause several damages to neural cells including death. Recent studies show that the glutamate agonist N-methyl-d-aspartate (NMDA) can trigger acute lung injury (ALI). ALI is a direct and indirect injury to alveolar epithelial cells and capillary endothelial cell, causing diffuse pulmonary interstitial and alveolar edema and acute hypoxic respiration failure. ALI is characterized by reduced lung volume and compliance, and imbalance of the ventilation/perfusion ratio, inducing hypoxemia and respiratory distress and its severe stage (oxygen index <200) known as acute respiratory distress syndrome (ARDS). (1) Furthermore, pathological findings show that 64% of ARDS patients may have pulmonary fibrosis during convalescence (2).
NP-120 (Ifenprodil) was initially developed by Sanofi in the 1970’s in the French and Japanese markets for the treatment of circulatory disorders. The drug is genericized and sold in Japan and South Korea only and is used to treat certain neurological conditions.
About Algernon Pharmaceuticals Inc.
Algernon Pharmaceuticals is a clinical stage pharmaceutical development company focused on advancing its lead compounds for non–alcoholic steatohepatitis (NASH), chronic kidney disease (CKD) inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF), and chronic cough. ??
Algernon has filed new intellectual property rights globally for NP-120 (Ifenprodil) for the treatment of respiratory diseases and is working to develop a proprietary injectable and slow release formulation.??
CONTACT INFORMATION
Christopher J. Moreau?CEO?Algernon Pharmaceuticals Inc.?604.398.4175 ext 701?info@algernonpharmaceuticals.com?investors@algernonpharmaceuticals.com?www.algernonpharmaceuticals.com
The CSE does not accept responsibility for the adequacy or accuracy of this release.
Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. The Canadian Securities Exchange has not in any way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.
CAUTIONARY DISCLAIMER STATEMENT: No Securities Exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.
(1) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5938426/?(2) https://www.ncbi.nlm.nih.gov/pubmed/19909524
Where can I finds information about it no longer being suspended?
I just put 1,000,000 shares up for sale at 0.0001. If anyone is having issues buying and still can’t get any if they try again now - then you most likely have a brokering issue.
So... I have several questions.
The first one is why is this news release not showing up on OTCMarkets.com? The more I look at the one posted here, the more I’m thinking it was photoshopped or something. Regardless - if it was there - why is it not there now? It would be there for ever, wouldn’t it?
The part about them issuing 12 million shares to the company they are merging with after the 1:10,000 RS is odd as well.
That basically equates to 120,000,000,000 (yes - 120 billion shares at today’s value).
There are only 1,000,000,000 currently in the AS. So why even bother with any of this? This math has them giving away 99.2% of the company to the company merging in. There are definitely easier and less damaging (and less expensive ways) to accomplish this, right?
I don’t know... it all seems like a basher has gotten your shares. IMO
Any thoughts or insights feel free to chime in
So what is the proposed RS? Ie is it 1:1000? Etc
Yes. I thought I read this morning that it was a 2 week suspension. I could be wrong... will look again.
There was not any notice by Trina or anyone else representing the massive 1:2000 Reverse Split on this stock.
People found out about it as it appeared in the FINRA report. Trina was silent - nowhere to be found. I tried calling him, emailing him, and messaging him on Facebook - no response to this day.
He also didn’t RS his own stock for about a month.
Also - this was the 5th Reverse Split on this stock by him over the years.
He is THE example of rinse and repeat.
Does anyone have the cheat sheet for MM code for shares amounts traded? I’m unable to locate atm.
Example: 100 shares = ??
Etc
When this runs, and it will run imo, it will run to .0015 on the first day or two.
It’s about to run again... #OPTI
Um.... we are 6 times what you are saying we won’t get to. Lol
I’m guessing you meant $0.10?
Either way - this one is a steal. Been adding since my dd last week. Still adding.
GLTA
Solid volume this week. Things may be looking up
GLTA
$MLHC
Deal has been completed:
TORONTO, ONTARIO, April 21, 2019 – MPX International Corporation (“MPX International”, “MPXI” or the “Company”) (CSE:MPXI; OTC:MPXOF) is pleased to announce that it has completed the previously announced acquisition of all of the outstanding shares of HolyWorld SA (“HolyWeed”) from Romain Gruner, Bernard Rappaz and Laurent Rappaport (the “Shareholders”) for a total purchase price of CHF10,000,000 (CDN$13,384,000 calculated using a deemed exchange rate of CDN$1.34 for each CHF 1.00) (the “Purchase Price”).
Pursuant to the terms of the definitive agreement, MPXI satisfied the Purchase Price through the issuance of 25,252,830 common shares of MPXI (the “MPXI Shares”) to the Shareholders at price of CDN$0.53 per MPXI Share. 80% of the MPXI shares issued to the shareholders of HolyWeed will be placed in a voluntary escrow to be released to the shareholders upon the occurrence of the following:
1. 20% of the MPXI Shares issued to the Shareholders will be released to the Shareholders upon the official launch and sale of cannabidiol oil on the HolyWeed eCommerce Platform;
2. 20% of the MPXI Shares issued to the Shareholders will be released to the Shareholders upon confirmation of an annualized revenue run-rate of CHF 5,000,000.-; and
3. 40% of the MPXI Shares issued to the Shareholders will be released to the Shareholders upon confirmation of achieved EBITDA of CHF1,600,000.- for the twelve month trailing period.
If the release conditions have not been satisfied by June 30, 2021, any MPXI Shares remaining in Escrow shall be automatically released by the Escrow Agent to MPXI for cancellation.
HolyWeed, which is the only Swiss CBD brand awarded the official ‘Swiss Certified Organic’ label, has a diverse product range which includes 100% Swiss grown cannabis light/high CBD pre-rolls, dry flowers, sublingual oils and cosmetics, all compliant with Swiss regulations of <1% THC. HolyWeed will be harvesting over 25,000 kilograms of high-CBD dry cannabis flowers later this year. HolyWeed’s wholesale distribution network spans more than 4,000 kiosks across Switzerland and will soon expand to wider export markets across Europe. HolyWeed products are also available for sale online and delivered free of charge by courier across Switzerland within 24 hours. HolyWeed also plans to open branded retail stores in Geneva and Zurich.
MPXI will develop a GMP-certified manufacturing facility to produce CBD extracts and isolates for both HolyWeed and export. The facility will feature a full-scale commercial kitchen and a formulation R&D laboratory, giving MPXI the ability to develop innovative CBD products and to potentially collaborate with local partners.
“The acquisition of HolyWeed is a major step in MPX International’s expansion strategy,” stated W. Scott Boyes, MPXI’s Chairman, President and CEO. “HolyWeed brings to our company a well-recognized brand and a solid opportunity to expand into other legal ‘cannabis-light’ markets in Europe.”
About MPX International Corporation
MPX International Corporation is focused on developing and operating assets across the global cannabis industry with an emphasis on cultivating, manufacturing and marketing products which include cannabinoids as their primary active ingredient.
About HolyWeed
Co-founded in 2017 by celebrity Swiss cannabis pioneer Bernard Rappaz, HolyWeed is the only Swiss CBD brand officially ‘Swiss Certified Organic’. HolyWeed has built one of the most professional management teams in the Swiss CBD sector and has demonstrated a strong branding expertise while continuously focusing on innovative product development. Fully verticalized, from seed to sale, Holyweed is one of the largest outdoor CBD cultivators in Western Europe with a highly competitive cost of production. For more information about HolyWeed, please visit www.holyweed.ch.
Cautionary Statement Regarding Forward-Looking Information
This news release includes certain “forward-looking statements” under applicable Canadian securities legislation that are not historical facts. Forward-looking statements involve risks, uncertainties, and other factors that could cause actual results, performance, prospects, and opportunities to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements in this news release include, but are not limited to, MPX International’s objectives and intentions. Forward-looking statements are necessarily based on a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic and social uncertainties; litigation, legislative, environmental and other judicial, regulatory, political and competitive developments; delay or failure to receive board, shareholder or regulatory approvals; those additional risks set out in MPX International’s public documents filed on SEDAR at www.sedar.com; and other matters discussed in this news release. Although MPX International believes that the assumptions and factors used in preparing the forward-looking statements are reasonable, undue reliance should not be placed on these statements, which only apply as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Except where required by law, MPX International disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.
For further information, please contact:
MPX International Corporation
W. Scott Boyes, Chairman, President and CEO
T: +1-416-840-3725
info@mpxinternationalcorp.com
www.mpxinternationalcorp.com
Nobody is buying here because if you instead buy $MLHC, then in a week or so you’ll get these shares for free.
Easy decision.
But once that deal and share dividend goes through - this one should move north at a steady pace, IMO.
GLTA
Huge news:
MPX International Acquires HolyWeed, a Swiss Premium Organic Cannabis Company
Wednesday, April 10, 2019 7:30 AM
TORONTO, ON / ACCESSWIRE / April 10, 2019 / MPX International Corporation ("MPX International", "MPXI" or the "Company") (CNSX: MPXI; OTC PINK: MPXOF) is pleased to announce that it has entered into a definitive agreement to purchase all outstanding shares of HolyWorld SA ("HolyWeed") from Romain Gruner, Bernard Rappaz and Laurent Rappaport (the "Shareholders"). This acquisition represents a major step in MPXI's expansion strategy, adding a highly recognized brand to its portfolio, as well as one of the largest Western European outdoor cultivators of high-CBD flowers.
Pursuant to the terms of the Purchase Agreement, MPXI will acquire all of the HolyWeed Shares for a total purchase price of CHF10,000,000 (CDN$13,384,000 calculated using a deemed exchange rate of CDN$1.34 for each CHF1.00 for the purposes of this resolution which number shall be adjusted upwards or downwards to the extent necessary using the exchange rate posted at the close of business by the Bank of Canada five (5) days prior to closing) through the issuance of common shares of MPXI (the "MPXI Shares") at price of CDN$0.53 per MPXI Share. MPXI will issue approximately 25,252,830 MPXI Shares to the shareholders of HolyWeed which number shall be adjusted upwards or downwards to the extent necessary using the exchange rate posted at the close of business by the Bank of Canada five (5) days prior to closing.
HolyWeed's product range includes 100% Swiss grown cannabis light/high CBD pre-rolls, dry flowers, sublingual oils and cosmetics, all compliant with Swiss regulations of <1% THC. They are the only Swiss CBD brand awarded the official 'Swiss Certified Organic' label and will be harvesting over 25,000kg of high-CBD dry cannabis flowers later this year. HolyWeed's wholesale distribution network spans more than 4,000 kiosks across Switzerland and will soon expand to wider export markets across Europe. HolyWeed products are also available for sale online and delivered free of charge by courier across Switzerland within 24 hours. HolyWeed also plans to open branded retail stores in Geneva and Zurich.
Complementing the acquisition, MPXI will develop a GMP-grade manufacturing facility to produce CBD extracts and isolates for both HolyWeed and export. The facility will feature a full-scale commercial kitchen and a formulation R&D laboratory, giving MPXI the ability to develop innovative CBD products and to collaborate with local partners.
"Switzerland is home to some of the most advanced consumer goods, cosmetics, ingredients and pharmaceutical companies in the world, and HolyWeed being on their doorstep opens a whole host of future opportunities," said Daniel Fryer, MPXI's Head of European Development.
In February of this year, the Swiss government announced plans for a pilot test which would result in temporary licenses for local cannabis companies to produce and sell higher THC marijuana for adult consumer use within a regulated framework. Final details of the program are to be released later this year.
"The acquisition of this exciting Swiss participant in the emerging European cannabis market represents our first foray outside of Canada" noted W. Scott Boyes, MPXI's Chairman, President and CEO. "HolyWeed brings to our company a strong local management team, a well-recognized brand of products and a solid opportunity to expand into other legal 'cannabis-light' markets in Europe."
"Merging HolyWeed with MPXI represents a unique opportunity to leverage our first-mover advantage in Switzerland and to develop our operations internationally with the support, expertise and best-in-class track record of the MPXI management team" remarks Bernard Rappaz, co-founder of HolyWeed. "I am delighted and excited to continue my life long mission to offer to the world the fantastic benefits of cannabis".
Upon closing, 80% of the MPXI shares issued to the shareholders of HolyWeed will be placed in a voluntary escrow to be released to the shareholders upon the occurrence of the following:
20% of the MPXI Shares issued to the Shareholders will be released to the Shareholders upon the official launch and sale of cannabidiol oil on the HOLYWORLD eCommerce Platform;
20% of the MPXI Shares issued to the Shareholders will be released to the Shareholders upon confirmation of an annualized revenue run-rate of CHF5,000,000;
40% of the MPXI Shares issued to the Shareholders will be released to the Shareholders upon confirmation of achieved EBITDA of CHF1,600,000 for the twelve-month trailing period.
If the Release Conditions have not been satisfied by June 30, 2021, any MPXI Shares remaining in Escrow shall be automatically released by the Escrow Agent to MPXI for cancellation.
About MPX International Corporation
MPX International Corporation is focused on developing and operating assets across the global cannabis industry with an emphasis on cultivating, manufacturing and marketing products which include cannabinoids as their primary active ingredient.
About HolyWeed
Co-founded in 2017 by celebrity Swiss cannabis pioneer Bernard Rappaz, HolyWeed is the only Swiss CBD brand officially 'Swiss Certified Organic'. HolyWeed has built one of the most professional management teams in the Swiss CBD sector and has demonstrated a strong branding expertise while continuously focusing on innovative product development. Fully verticalized, from seed to sale, Holyweed is one of the largest outdoor CBD cultivators in Western Europe with a highly competitive cost of production. For more information about HolyWeed, please visit www.holyweed.ch.
Cautionary Statement Regarding Forward-Looking Information
This news release includes certain "forward-looking statements" under applicable Canadian securities legislation that are not historical facts. Forward-looking statements involve risks, uncertainties, and other factors that could cause actual results, performance, prospects, and opportunities to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements in this news release include, but are not limited to, MPX International's objectives and intentions. Forward-looking statements are necessarily based on a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic and social uncertainties; litigation, legislative, environmental and other judicial, regulatory, political and competitive developments; delay or failure to receive board, shareholder or regulatory approvals; those additional risks set out in MPX International's public documents filed on SEDAR at www.sedar.com; and other matters discussed in this news release. Although MPX International believes that the assumptions and factors used in preparing the forward-looking statements are reasonable, undue reliance should not be placed on these statements, which only apply as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Except where required by law, MPX International disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.
For further information, please contact:
MPX International Corporation
W. Scott Boyes, Chairman, President and CEO
T: +1-416-840-3725
info@mpxinternationalcorp.com
www.mpxinternationalcorp.com
SOURCE: MPX International Corporation
MLHC ran up to .0025 about 4 months ago. It can easily do it again.
I’m pretty sure it will
Lol. You buy stocks at $0.0001 with no bid? Good strategy! Lmao
There’s lots of those out there.
In the meantime... still tons of action of $MLHC, and it will run again, IMO.
The last run went up 12 times its current value, and that wasn’t so long ago.
It has certainly as a group of companies made a lot of positive moves since then. I’m expecting to make even more on it this time then years last time.
GLTA
$MLHC
Wow!
I can’t believe I just got 0002’s!
Thanks to whomever dumped them.
$MLHC
Lmao!
Sounds like you have realized you shouldn’t have shorted this one.
Why don’t you check out the cash reserves this company has.
Also read up on how over a billion dollars has already been put aside (court mandated mind you) by Vale to deal with the class action.
They are a very successful and profitable company working mines of various minerals all over the world. While what happened in Brazil was a disaster, and a tragedy, it seems to be someone they are well equipped to handle financially, imo.
Oh, and world bank. LMAO!
This stock being uplifted will never happen with Trina having any involvement in it.